Down -23.95% in 4 Weeks, Here's Why Relay Therapeutics (RLAY) Looks Ripe for a Turnaround
H.C. Wainwright Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Raises Target Price to $20
Relay Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Relay Therapeutics Price Target Raised to $20.00/Share From $19.00 by HC Wainwright & Co.
A Quick Look at Today's Ratings for Relay Therapeutics(RLAY.US), With a Forecast Between $17 to $27
JMP Securities Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Maintains Target Price $21